Scott Nicholas Gettinger, MD

Associate Professor of Medicine (Medical Oncology)

Clinical Interests

  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Internal Medicine: Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Thoracic Oncology Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine)

Clinical Trials

Conditions Study Title
Lung Phase 3 - Nivo, or Nivo+Ipilmumab vs. platinum doublet chemo in chemotherapy-naive stage 4 or NSCLC
Lung Phase 3 study of MEDI4376+Tremelimumab or MEDI4376 Monoherapy vs. SoC Platinum Based Chemo in NSCLC
Lung Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent NSCLC
Lung CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Lung A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat
Lung Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Lung S1403
Lung PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Lung, Phase I A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o
Lung Safety and Efficacy of Abraxane Maintenance post Abraxane + Carboplatin in squamous cell lung cancer
Lung Biomarker-Driven Master Protocol for Squamous Cell Lung Cancer
Melanoma, skin PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Breast - Female, Lung, Ovary, Pancreas, Stomach, Phase I Phase 1/2 Study of Nivolumab or Nivolumab with Ipilimumab for Advanced or Metastatic Solid Tumors
Lung Lung Cancer Mutation Consortium Protocol
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid, Phase I PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Scott Nicholas Gettinger, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208028
New Haven, CT 06520-8028